XML 96 R45.htm IDEA: XBRL DOCUMENT v3.25.0.1
Share-Based Compensation (Tables)
12 Months Ended
Dec. 31, 2024
Share-Based Compensation [Abstract]  
Schedule of Company Granted Options

In the years ended December 31, 2024, and 2023, the Company granted options as follows:

 

   Year ended December 31, 2024 
   Award
amount
   Exercise
price
   Vesting
period
   Expiration 
Employees   65,957    0.23 NIS    4 years    10 years 
Employees   378,901    $9.44-$10.88    4 years    10 years 
Directors   75,957    0.23 NIS    4 years    10 years 
Subcontractors   4,390    0.23 NIS    4 years    10 years 
Subcontractors   16,834    $9.67-$10.48    4 years    10 years 
Total granted   542,039                

 

   Year ended December 31, 2023 
   Award
amount
   Exercise
price
   Vesting
period
   Expiration 
Employees   339,185    0.23 NIS    4 years    10 years 
Subcontractors and directors   4,997    0.23 NIS    4 years    10 years 
Total granted   344,182                
Schedule of Fair Value of the Options

The underlying data used for computing the fair value of the options (as of the grant date) are as follows:

 

   2024   2023 
Employees          
Expected term (years) —   6.11    5.91-6.14 
Expected volatility   43.48%   40.98% - 42.14%
Risk free interest rate   4.30%   3.80%-3.83%
Expected dividend yield   0.00%   0.00%
Exercise price   0.06-10.48    0.06 
           
Non-Employees          
Expected term (years) —   10.00    10.00 
Expected volatility   43.48%   42.09%-42.17%
Risk free interest rate   4.30%   3.64%-3.75%
Expected dividend yield   0.00%   0.00%
Exercise price   0.06-10.48    0.06 
           
Assumptions regarding the price of the underlying shares:          
Probability of an IPO   30%   25%
Expected time to IPO (years)   0.5    0.75 
Probability of liquidation event   70%   75%
Expected time to liquidation (years)   2.0    2.0 
Schedule of Outstanding and Exercisable Options

The following table summarizes the number of options outstanding for the years ended December 31, 2024 and December 31, 2023, and related information:

 

   Number of
options
   Weighted-
average
exercise
price
   Weighted-
average
remaining
contractual
term (in years)
   Aggregate
Intrinsic
Value
(in U.S. dollars)
 
Outstanding at December 31, 2023   1,300,475   $0.066    7.75   $14,109 
Granted   542,039   $7.667    9.85   $
-
 
Exercised   (186,038)  $0.062    (6.82)  $1,508 
Forfeited   (23,684)  $4.466    (8.86)  $
-
 
Expired   (2,219)  $0.065   
 
   $
-
 
Outstanding at December 31, 2024   1,630,573   $2.5259    7.63   $12,274 
                     
Exercisable at December 31, 2024   947,700   $0.518    6.67   $8,938 
Vested and expected to vest at December 31, 2024   1,630,573   $2.529    7.63   $12,274 
   Number of options   Weighted-
average
exercise
price
   Weighted- average remaining contractual term (in years)   Aggregate
Intrinsic
Value
(in U.S. dollars)
 
Outstanding at December 31, 2022   1,008,927   $0.068    8.12   $9,601 
Granted   344,182   $0.063    9.80   $
-
 
Exercised   (23,254)  $0.062    (7.10)  $224 
Forfeited   (24,374)  $0.067    (8.91)  $
-
 
Expired   (5,006)  $0.070    
-
   $
-
 
Outstanding at December 31, 2023   1,300,475   $0.066    7.75   $14,109 
                     
Exercisable at December 31, 2023   818,625   $0.067    7.28   $8,881 
Vested and expected to vest at December 31, 2023   1,300,475   $0.066    7.75   $14,109 
Schedule of Company’s Nonvested Employee Options

The following table summarizes the number of options outstanding for the years ended December 31, 2024 and December 31, 2023, and related information:

 

   Number of
options
   Weighted-
average
grant-date
fair value
price
 
Outstanding at December 31, 2023   481,850    9.68 
Granted   542,039    13.25 
Vested   (317,304)   9.99 
Forfeited   (23,684)   10.83 
           
Outstanding at December 31, 2024   682,901    12.33 
           
Outstanding at December 31, 2022   458,218    8.24 
Granted   344,182    10.80 
Vested   (296,176)   8.76 
Forfeited   (24,374)   9.53 
           
 Outstanding at December 31, 2023   481,850    9.68 
Schedule of Consolidated Statements of Operations

The share-based compensation expense by line item in the accompanying consolidated statements of operations is summarized as follows:

 

   Year ended December 31 
   2024   2023 
Cost of sales  $303   $139 
Research and development   610    240 
General and administrative   4,975    1,964 
Sales and marketing   719    224 
   $6,607   $2,567